Medicine and Dentistry
Interstitial Lung Disease
100%
Idiopathic Pulmonary Fibrosis
90%
Patient
73%
Therapeutic Procedure
43%
Pulmonary Fibrosis
36%
Diagnosis
36%
Infection
33%
Lung
28%
COVID-19
21%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Forced Vital Capacity
19%
Mortality
18%
Diseases
18%
Inpatient
18%
Combination Therapy
18%
Disease Exacerbation
18%
Personalized Medicine
17%
Quality of Life
16%
Adverse Event
15%
Deterioration
14%
Sarcoidosis
14%
Longevity
13%
Mycophenolate Mofetil
13%
Usual Interstitial Pneumonia
13%
Dasatinib
13%
Quercetin
13%
Acetylcysteine
13%
Patient Registry
13%
Health Outcomes
13%
Clinical Trial
13%
Cough
13%
Stress
13%
Genotype
13%
Vasoactive Agent
13%
Systematic Review
13%
Pulmonary Hypertension
13%
Virus Antigen
13%
Phosphodiesterase
13%
High-Resolution Computed Tomography
12%
Silo-Filler's Disease
11%
Age
11%
Biological Marker
10%
Lung Emphysema
10%
Trimethoprim/Sulfamethoxazole
10%
Doxycycline
10%
Antiinfective Agent
10%
Placebo
10%
Coughing
9%
Sequela
8%
Follow up
8%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosing Alveolitis
60%
Quercetin
27%
Dasatinib
27%
Mouse
15%
Adverse Event
15%
Clinical Trial
14%
Antiinfective Agent
14%
Diseases
14%
Interstitial Lung Disease
13%
Ceftaroline
13%
Mycophenolate Mofetil
13%
Acetylcysteine
13%
Interstitial Lung Disease
13%
Esophagus Foreign Body
13%
Sore Throat
13%
Lung Fibrosis
13%
Fibrosing Alveolitis
13%
Phosphodiesterase
13%
Human
12%
Randomized Controlled Trial
10%
Placebo
10%
Cotrimoxazole
10%
Doxycycline
10%
Community Acquired Pneumonia
6%
Death
6%
Hoarseness
6%
Stridor
6%
Disease Exacerbation
5%
Infection
5%
